SUMMARY

OncologySTAT Editorial Team

Surgery is usually curative for patients with early-stage carcinoid or pancreatic neuroendocrine cancer. This is often not an option for patients with advanced disease, for whom limited treatment options exist. Somatostatin analogs can alleviate symptoms of hormone secretion, but they rarely lead to tumor regression. Up to 10% of patients respond to interferon alfa treatment; therapy may be limited, however, by fatigue, myelosuppression, and depression. Prolonged use of streptozocin- or temozolomide-based...